"ASCO 2019: Lymphoma Expert Discusses Advances in Targeted Therapies"
Joshua Brody, MD, director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai discusses advances at ASCO 2019. “One of the big advances for patients with lymphoma are targeted therapies. Immune therapies are also a big advancement, where we get our patients own immune systems to go in and attack their own cancer.” He added, “For some of these patients who have had chemotherapy, they want something that kills cancer in a different way, and this is a great example of that.”
— Joshua Brody, MD, Director, Lymphoma Immunotherapy Program, The Tisch Cancer Institute, Assistant Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai